Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Journal for Immunotherapy of Cancer|October 31, 2020
Autoimmunity linked protein phosphatase PTPN22 as a target for cancer immunotherapyRafael Cubas, Zia Khan, Qian Gong, et al.Journal of Immunology (Baltimore, Md. : 1950)|September 14, 2018
Chemotherapy Combines Effectively with Anti-PD-L1 Treatment and Can Augment Antitumor ResponsesRafael Cubas, Marina Moskalenko, Jeanne Cheung, et al.Proceedings of the National Academy of Sciences of the United States of America|April 15, 2018
Role of PD-1 during effector CD8 T cell differentiationEunseon Ahn, Koichi Araki, Masao Hashimoto, et al.Science (New York, N.Y.)|March 11, 2017
T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibitionEnfu Hui, Jeanne Cheung, Jing Zhu, et al.Immunity|March 6, 2016
MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint BlockadePeter J R Ebert, Jeanne Cheung, Yagai Yang, et al.Signal Transduction and Targeted Therapy|July 16, 2026
A cell-based kinetic framework enables TCR specificity predictionMartin Culka, Jonathan Desponds, Jeanne Cheung, et al.The Journal of Clinical Investigation|May 4, 2006
IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6David Yen, Jeanne Cheung, Heleen Scheerens, et al.Nature Communications|February 22, 2017
Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in miceJanet Lau, Jeanne Cheung, Armando Navarro, et al.Nature Cancer|February 5, 2022
PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancerSoyoung A Oh, Dai-Chen Wu, Jeanne Cheung, et al.Journal of Immunology (Baltimore, Md. : 1950)|May 23, 2002
A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23RChristi Parham, Madaline Chirica, Jacqueline Timans, et al.Pageof 2